Brexpiprazole in clinical practice or art of schizophrenia treatment oriented toward the functional remission
2021
Abstract
Brexpiprazole is a new antipsychotic that belong to dopamine receptor partial agonist (DRPA). We present seven case studies that represent prosperous use of brexpiprazole in complex treatment of schizophrenia.
Not only psychiatrists but patients appreciate weight loss, absence of sedation, akathisia, neuroleptic dysphoria and return to society, study or working activities together with improvement of positive and negative symptoms with brexpiprazole treatment. The case studies documented that brexpiprazole is not exchangeable with other antipsychotics.
Brexpiprazole meants enrichment of treatment, because patients might reach the functional remission of schizophrenia and substantial quality of life improvement.